Clinical Trials in Seattle

Showing 6561-6580 of 9,312 trials

Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

NCT02966587

This phase II trial studies how well durvalumab works in treating patients with prostate cancer that is resistant to hormones and has spread to other places in the body. Monoclonal antibodies, such as durvalumab, may interfere with the ability of tumor cells to grow and spread.

Castration Levels of TestosteroneHormone-Resistant Prostate CancerMicrosatellite Instability

University of WashingtonStarted May 2018

Seattle, Washington, United States

COMPLETEDPhase 3< 1 mile

Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects

NCT01449929

This study will be conducted in approximately 468 HIV-1 infected antiretroviral therapy (ART)-naïve subjects. Subjects will be randomized 1:1 to receive dolutegravir (DTG) 50 mg once daily (approximately 234 subjects) or darunavir/ritonavir (DRV/r) 800 mg/100 mg once daily (approximately 234 subjects), each in combination with fixed-dose dual nucleoside reverse transriptase inhibitor (NRTI) therapy (either abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC). Subjects will be stratified by screening HIV-1 RNA and background NRTI selection. The primary analysis will take place after the last subject completes 48 weeks on therapy; an additional analysis will be conducted after the last subject completes Week 96 on study.

Infection, Human Immunodeficiency Virus

ViiV Healthcare488 participantsStarted Oct 2011

Birmingham, Alabama, United States • Los Angeles, California, United States • Los Angeles, California, United States +63 more locations

Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects

Find Trials by Condition in Seattle

Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma

A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer

Phase II Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft

Associations Between Pre-transplant Comorbidities and Post-transplant Toxicities and Quality of Life

OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma

A Safety Study of SGN-CD33A in AML Patients

Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma

FreeStyle Libre Flash Accuracy Study

DTS Blood Glucose Monitor System Surveillance Program SubStudy 1

A Study in Type 2 Diabetics of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics

OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.

Simvastatin Therapy for Moderate and Severe COPD

CardiAQ-Edwards™ Transcatheter Mitral Valve Replacement (TMVR) Study

A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.

A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects

Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma

3-year Follow-up Study to Assess the Viral Activity in Hepatitis C Patients Who Failed Feeder DEB025/Alisporivir Study